Adding immunotherapy (nivolumab) to chemotherapy before surgery significantly improved long-term overall survival for patients with operable non-small cell lung cancer (NSCLC) compared to chemotherapy alone.
Adding immunotherapy (nivolumab) to chemotherapy before surgery significantly improved long-term overall survival for patients with operable non-small cell lung cancer (NSCLC) compared to chemotherapy alone.
Read More
A deep learning model was able to predict future lung cancer risk from a single low-dose chest CT scan.
Read More
Healthy Lungs California will expand its early lung cancer screening initiative thanks to a partnership between the University of California Lung Cancer Consortium and AstraZeneca.
Read More
Medicaid expansion under the Affordable Care Act was associated with an increase in lung cancer surgeries performed at high-volume hospitals, which are associated with decreased rates of postoperative complications and in-hospital mortality rates.
Read More
ACS says 3.8 million lung cancer deaths were averted and over 76 million years of life gained in the United States during 1970-2022 due to substantial reductions in smoking prevalence driven by tobacco control.
Read More
New data show Rybrevant plus Lazcluze extends overall survival in patients with EGFR-mutated non-small cell lung cancer, with the median survival benefit expected to exceed one year compared to osimertinib.
Read More
The American Lung Association emphasizes that smoking combined with radon exposure significantly increases lung cancer risk and is intensifying efforts to raise awareness through testing resources and smoking cessation support.
Read More
Gilead Sciences’ Trodelvy receives FDA Breakthrough Therapy Designation for the treatment of extensive-stage small cell lung cancer.
Read More
The FDA says the approval marks the first systemic therapy for non–small cell lung cancer and pancreatic adenocarcinoma harboring NRG1 gene fusions.
Read More
The widely used diabetes drug seems to strengthen the immune system’s tumor-killing response in overweight and obese lung cancer patients.
Read More
American Lung Association’s ‘State of Lung Cancer’ report reveals stark differences in survival, screening and treatment across states.
Read More
In small-scale tests, the nanoscale sensors distinguished a key change in the chemistry of the breath of people with lung cancer.
Read More
During Lung Cancer Awareness Month, the American Lung Association’s Lung Force initiative is raising awareness about the role of early detection, screening, and biomarker testing in improving lung cancer survival rates.
Read More
The AI module is intended to support physicians by evaluating bronchoscopic lung forceps biopsies on-site.
Read More
Patients with chronic conditions like COPD and asthma are diagnosed with lung cancer significantly later than those without these conditions.
Read More
The combination regimen was approved for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer with specific EGFR mutations.
Read More
The approval was based on trial results which showed the regimen reduced the risk of recurrence, progression, or death by 32% versus neoadjuvant chemotherapy alone.
Read More
The FDA granted Fast Track designation to Deltacel, a Gamma Delta T-cell therapy being developed for the treatment of advanced non-small cell lung cancer.
Read More
Researchers discovered that 42% of non-smoking adults had lung nodules, with 11.1% of these cases involving clinically significant nodules typically associated with higher-risk groups.
Read More
The phase 3 trial was investigating the vibostolimab and pembrolizumab combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Read More
The American Lung Association and Protect Environmental are providing access to free radon test kits to homeowners in select communities to raise awareness about radon, the second leading cause of lung cancer.
Read More
The American Lung Association releases data that examines knowledge about lung cancer on World Lung Cancer Day.
Read More
The investigational therapy, targeting the B7-H3 antigen, has shown promising tumor-killing effects and a good safety profile in preclinical models.
Read More
Scientists have linked high levels of violent crime to aggressive lung cancer tumors, suggesting chronic stress as a potential driver.
Read More
